Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Private Wealth

Navigating residency and domicile planning with Russian nexus in the pharmaceuticals sector: a step-by-step overview

Elizaveta Razina · January 2026 · 10 min read

Pharmaceutical executives with Russian assets face distinct residency and domicile risks. A step-by-step guide for wealth advisers. Make an enquiry.

Foreign pharmaceutical executives and their wealth advisers who maintain assets, licensing arrangements, or employment relationships inside Russia occupy an unusually exposed position in residency and domicile planning. The sector's regulatory architecture — spanning Roszdravnadzor licensing, distribution agreements with Russian entities, and the employment of locally registered directors — creates multiple legal nexus points that Russian authorities and creditors can use to assert claims against an individual, even where that individual has long since relocated abroad. A well-sequenced planning process, begun before formal proceedings arise, remains the most effective tool available under Russian law.

What to prepare before beginning

Gathering the right documentation at the outset determines the pace and quality of every subsequent step. For pharmaceutical sector principals, the relevant materials differ materially from those relevant to, say, a real estate investor.

This documentation set is the foundation for the analysis in Steps 1 through 5.

For a confidential review of your documentation position before proceeding, please contact the team: info@vetrovpartners.com |

Step 1 — Map the Russian nexus points specific to pharmaceutical activities

The pharmaceutical sector generates nexus points that general wealth-planning frameworks do not anticipate. A principal whose name appears on a Roszdravnadzor marketing authorisation, who has personally guaranteed the obligations of a Russian distribution entity, or who retains a registered directorship in a Russian operating company remains legally present in Russia for multiple regulatory purposes — irrespective of where that individual physically resides.

The first step is a systematic audit of every Russian-law instrument in which the individual is named or has an obligation. This covers not only shareholding structures but also the regulatory licences without which pharmaceutical products cannot be placed on the Russian market. In many structures, foreign principals have been named as responsible officers in licence applications as a matter of administrative convenience — a designation that carries personal liability under Russian regulatory law and, potentially, under Russian criminal procedure if the licensed product is later the subject of a quality or counterfeit investigation.

EAEU membership introduces a further dimension. Russia's participation in the Eurasian Economic Union means that pharmaceutical marketing authorisations often operate across EAEU member states simultaneously, and that an individual named on an EAEU-format authorisation may face regulatory exposure in multiple CIS jurisdictions in addition to Russia itself.

The output of Step 1 is a nexus map: a document listing every Russian-law or EAEU-law instrument creating a personal obligation or regulatory presence, ranked by risk profile.

Step 2 — Establish current tax residency position and identify the change-of-status trigger

Residency domicile planning with Russian nexus cannot proceed without first establishing the individual's current position under Russian tax law. Russian tax legislation applies a 183-day physical-presence test within a 12-month period. An individual who was physically present in Russia for fewer than 183 days in the preceding calendar year is, as a general rule, a non-resident for Russian income tax purposes — but this does not extinguish all Russian tax obligations on Russian-source income.

For pharmaceutical sector principals, Russian-source income commonly includes royalties from licensing agreements with Russian entities, consultancy fees paid by Russian pharmaceutical distributors, and dividends from Russian subsidiaries or joint-venture companies. Each of these income streams remains taxable in Russia regardless of the recipient's residency status, and the withholding rate applicable to non-residents is materially higher than that applied to residents.

Wealth advisers should also note that CIS member states maintain a network of tax treaties with Russia under both the CIS multilateral framework and bilateral instruments. The interaction between these treaties and Russian domestic tax law is not always settled, and in the pharmaceutical sector — where royalty flows are structurally common — treaty characterisation of income as a royalty versus a service fee can determine whether a reduced treaty rate applies.

The Step 2 output is a written residency position paper: the individual's status in each relevant calendar year, the income streams subject to Russian withholding, and the treaty analysis applicable to each stream.

Step 3 — Assess individual debtor exposure under Russian civil and insolvency law

Residency and domicile planning with Russian nexus individual debtors presents a distinct set of risks that fall outside the mainstream wealth-planning narrative. Where a pharmaceutical principal has provided personal guarantees to Russian banks or counterparties, those instruments remain enforceable under Russian law regardless of the guarantor's subsequent change of domicile.

Russian civil procedure allows creditors to seek enforcement of a guarantee or surety against an individual debtor through the arbitrazh courts (where the guarantee relates to a commercial dispute) or the courts of general jurisdiction. An individual who relocates abroad but retains Russian assets — including shares in Russian entities, real property, or receivables under licensing agreements — provides a natural enforcement target. Russian law individual debtors who have not taken steps to restructure their liability position before relocating may find that Russian creditors move to attach those assets through interim measures, including arrest orders applied for on an ex parte basis.

The pharmaceutical sector creates a specific risk here: distribution agreements frequently include personal guarantee provisions as a condition of commercial credit from Russian wholesale distributors. Where the principal of a foreign pharmaceutical company has signed such a guarantee personally — often without appreciating the full scope of Russian enforcement law — that obligation survives the individual's departure and can be enforced through standard debt-recovery proceedings.

Step 3 produces a liability schedule: all personal guarantee instruments, the estimated quantum of exposure, the likely enforcement forum, and whether any statute of limitations defence is available under Russian law.

Step 4 — Structure the exit from Russian regulatory and corporate positions

Having mapped the nexus points, established the residency position, and assessed individual debtor exposure, the next step is to sequence the exit from those Russian positions in a legally defensible order. The sequence matters because certain actions — resigning from a regulatory licence before a corporate restructuring is complete, for example — can trigger regulatory penalties or leave a licensing gap that Russian authorities treat as a violation.

The recommended sequence for pharmaceutical sector principals is as follows:

Identify a Russian-qualified successor responsible officer for any Roszdravnadzor licence on which the individual is named, and complete the transfer of regulatory responsibility before initiating any corporate restructuring.Resign from any Russian directorship only after the successor director has been registered with the Federal Tax Service and the relevant corporate documents have been filed with the unified state register of legal entities (EGRUL).Address outstanding guarantee obligations: either negotiate a release from Russian counterparties, replace the personal guarantee with a corporate security instrument, or set aside reserves within the overall wealth structure to meet the contingent liability if called.Undertake any asset restructuring — transfer of Russian assets to holding structures, pledge release, or sale of Russian real property — only after regulatory and corporate exits have been completed and documented.

This sequencing protects the individual from claims of constructive fraud or preferential asset-stripping under Russian insolvency legislation, which can be invoked where assets are moved in anticipation of creditor claims.

Step 5 — Establish and document the new domicile position

The final step is the construction of a defensible domicile position in the new jurisdiction, supported by documentation that will withstand challenge from Russian tax authorities or creditors seeking to assert that the individual remains Russian-resident for legal purposes.

Russian authorities have, in practice, applied heightened scrutiny to individuals with continuing Russian-source income who claim non-resident status, particularly where pharmaceutical royalty flows or consulting arrangements continue after the claimed change of domicile. The documentation standard required to rebut a residency challenge is therefore more demanding than the standard applicable in purely domestic relocation contexts.

Russian assets wealth planning in this context requires the following documentation package:

The new domicile position should be reviewed annually, particularly where EAEU-format pharmaceutical licences continue to generate income from Russia or other EAEU member states — since those income flows may give Russian tax authorities a basis to challenge the claimed non-resident status in subsequent years.

For in-house advisers and family office counsel managing a pharmaceutical principal's Russian exit, an early-stage structural review avoids the sequencing errors that create lasting exposure — contact the team in confidence: info@vetrovpartners.com |

Frequently asked questions

Q: How long does the residency change-of-status process typically take for a pharmaceutical principal with multiple Russian nexus points?

A: The timeline depends on the number of positions requiring an orderly exit. The regulatory transfer of a Roszdravnadzor licence responsibility is typically the longest element, and can take several months if Russian authorities request supplementary documentation from the successor officer. Corporate filings with EGRUL are generally completed within a matter of weeks once the underlying corporate resolutions are in place. In practice, a comprehensive process covering regulatory, corporate, and tax residency steps for a pharmaceutical principal with several active Russian positions commonly extends across two to three calendar years — not because each individual step is slow, but because the sequence requires each stage to be completed and documented before the next begins. Advisers should plan accordingly and not treat the process as a single transaction.

Q: What documents does Russian tax authority typically request when challenging an individual's claim to non-resident status?

A: In the authors' experience of similar matters, the Federal Tax Service most commonly requests: physical presence records (passport entry and exit stamps, airline ticket records), evidence of the individual's economic centre of life (where the individual's primary residence, principal bank accounts, and dependants are located), and documentation of the cessation of Russian-source employment or management activity. For pharmaceutical principals who continue to receive royalties or consultancy fees from Russian entities after the claimed date of domicile change, the tax authority frequently treats those continuing income flows as evidence that the individual's economic centre of life remains in Russia. Structuring those income flows through correctly documented assignment or termination agreements before the residency change is therefore essential.

Q: What happens if a personal guarantee given to a Russian counterparty is called after the individual has relocated and restructured their Russian asset position?

A: Russian civil law provides that a personal guarantee survives the guarantor's change of domicile and remains enforceable in the jurisdiction of the Russian court. If Russian assets have been transferred abroad prior to the call on the guarantee, a creditor may seek to challenge those transfers as preferences or fraudulent conveyances under Russian insolvency legislation, subject to limitation periods. The practical defence involves two elements: first, ensuring that any asset restructuring undertaken before the guarantee was called was completed at fair value and documented accordingly; and second, engaging Russian-qualified counsel promptly to assess whether any limitation period, procedural irregularity in the call notice, or substantive defence under the guarantee instrument itself is available. Waiting to engage counsel until enforcement proceedings have been initiated materially narrows the available options.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry